Physician profile
Mark G Speaker
NPI 1598793796
$2,496.54
in general payments reported to CMS, 2019-2025
12 companies · $621 in 2025
The $621 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $226 · 2021: $490 · 2022: $399 · 2023: $128 · 2024: $105 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $918.26 | 2019-2025 | Wavelight Ex500 Excimer Laser, Wavelight Plus, Wavelight Refractive Suite |
| Kala Pharmaceuticals, INC. | $398.75 | 2019-2022 | |
| Harrow Eye, LLC | $362.54 | 2024-2025 | |
| Eyevance Pharmaceuticals LLC | $279.02 | 2019-2021 | |
| Allergan, INC. | $184.41 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $142.13 | 2019-2023 | |
| Abbvie INC. | $75.89 | 2022 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Sun Pharmaceutical Industries INC. | $34.19 | 2021-2022 | |
| Shire North American Group INC | $23.29 | 2019 | |
| Biotissue Holdings INC. | $23.24 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Speaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.